drugset / Trial / NCT01861249

Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)

NCT01861249 ↗

Phase 2 Terminated 6 enrolled Sanofi
NaSingle-groupOpen-labelTreatment

Summary

Primary Objective: To assess the long term safety and tolerability of SAR339658 Secondary Objective: To assess the long term efficacy of SAR339658

Timeline

Start
2013-07
Primary completion
2014-05
Completion
2016-04

Outcome

Outcome not reported

Stopped (Enrollment): “Recruitment was early terminated due to slow recruitment. Not linked to any safety concern.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Vatelizumab Monoclonal antibody — Intravenous

Indications